Olufemi Olumide Aoko

Dr. Olufemi Olumide Aoko

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2023 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
OAOlufemi Olumide Aoko
Olufemi Olumide Aoko
TMTobias Maharaj
Tobias Maharaj
FBFiona Boland
Fiona Boland
DCDanny Cheriyan
Danny Cheriyan
JRJohn Ryan
John Ryan
Summary: Background: Non‐alcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease affecting approximately 25% of adults in the western world. Intragastric balloon (IGB) is an endoscopic bariatric therapy ‐a therapeutic endoscopic tool that has shown promise in inducing weight loss. Its role in the treatment of NAFLD is yet to be established.Aim: To evaluate the effect of IGB as a treatment option in NAFLD.Methods: We searched MEDLINE (PubMed) and EMBASE from inception to September 2022. We included studies evaluating the impact of IGB on obesity with the assessment of one or more liver‐related outcomes and studies primarily evaluating the impact of IGB on NAFLD. We included comparative and non‐comparative studies; primary outcomes were liver‐related NAFLD surrogates.Results: We included 19 studies with 911 patients. IGB demonstrated an effect on NAFLD parameters including NAFLD activity score (NAS): mean difference (MD): −3.0 [95% CI: −2.41 to −3.59], ALT: MD: −10.40 U/L [95% CI: −7.31 to −13.49], liver volume: MD ‐397.9 [95% CI: −212.78 to 1008.58] and liver steatosis: MD: −37.76 dB/m [95% CI: −21.59 to −53.92]. There were significant reductions in non‐liver‐related outcomes of body weight, BMI, glycated haemoglobin and HOMA‐IR.Conclusion: Intragastric balloons may play an important role in addressing the treatment gap in NAFLD management.

1 August 2022 in Research Square
Verified
Preprint
Open access
PDF file
OAOlufemi Olumide Aoko
Olufemi Olumide Aoko
GHG. Harewood
G. Harewood
RDR. Doherty
R. Doherty
KBK. Boland
K. Boland
JRJ. Ryan
J. Ryan
SPS. Patchett
S. Patchett
BACKGROUND Due to a huge focus of healthcare resources on acute COVID-19 care during the early phase of the pandemic, endoscopy activity worldwide was significantly reduced. This subsequently led to a reduction in the number of Oesophageal and Gastric cancers diagnosed during this period, resulting in delayed diagnosis. AIM To measure the impact of COVID-19 pandemic on the diagnosis of Oesophageal and Gastric cancers in a single tertiary referral centre. METHODS This was a retrospective study. Patients were divided into three groups based on the period of diagnosis. Period A represented October 2019 – March 2020, B represented April 2020-June 2020, and C represented July 2020-October 2020. Patients were then further subdivided based on the stage of the cancer at diagnosis. RESULTS A total of 153 patients diagnosed between October 2019 and October 2020 were included. The mean age was 69.4. During period B, which correlates with the early phase of the pandemic, and reduced endoscopy activity, there was a reduction in the number of cancers diagnosed. 66 patients (43.1%) were diagnosed in Period A, 25 (16.3%) in Period B and 62 (40.5%) in Period C. In respect to Period B, in comparison to the same period in 2019, 40 patients were diagnosed. There was also an increase in the number of cancers diagnosed at an advanced stage in Period C, correlating with the recovery/decelerating phase of the first wave of the pandemic. CONCLUSION This study highlights the risk associated with delayed diagnosis of Upper GI Cancers due to the pandemic.

16 October 2025 in Gastroenterology Insights
Verified
Journal Article
Open access
PDF file
MMMohamed Wael Mohamed
Mohamed Wael Mohamed
OAOlufemi Olumide Aoko
Olufemi Olumide Aoko
DCDanny Cheriyan
Danny Cheriyan
Background/Objectives: Cholecystectomy remains the gold-standard treatment for acute cholecystitis. However, in patients deemed unfit for surgery, alternative gallbladder drainage techniques are required. These include percutaneous gallbladder drainage (PT-GBD), endoscopic transpapillary gallbladder drainage (ET-GBD), and the more recently adopted endoscopic ultrasound-guided gallbladder drainage (EUS-GBD). EUS-GBD has emerged as a promising minimally invasive option, offering high technical and clinical success with fewer complications and need for reinterventions. The objective of this study was to evaluate the clinical outcomes of EUS-GBD in high-risk surgical patients with acute cholecystitis. Methods: We conducted a single-center retrospective study evaluating outcomes of EUS-GBD in a tertiary referral center in Ireland. Data from ten high-risk patients with acute cholecystitis who underwent EUS-GBD using a 15 mm × 10 mm HOT AXIOS lumen-apposing metal stent (LAMS) between October 2017 and September 2018 were analyzed. Parameters assessed included technical and clinical success, adverse events, and 1-year mortality. Results: The mean age of patients was 79.5 years (range 65–95). Technical success of stent placement was achieved in all patients with no immediate complications. A trans-gastric approach was used in 7 patients while a trans-duodenal route was employed in the remaining 3. 1–year mortality following EUS-GBD was 20%. Stents were not removed in any patient in this series. No patient experienced stent-related adverse events, re-occurrence of cholecystitis, or the need for re-intervention. Conclusions: EUS-GBD has very high technical and clinical success rates, with low risk of complications and need for re-intervention in comparison to other options of GB decompression. It is, however, not widely available, and it requires a skilled endoscopist with experience in interventional EUS.